Pharmaceutical industry – Page 36
-
Business
Cancer Drugs Fund axes 23 treatments
The UK government has cut down the list of cancer therapies it will pay for through the Cancer Drugs Fund
-
Business
Novartis to buy experimental MS drug from GSK in $1bn deal
Deal will help to bolster Novartis’s pipeline for neurological disorder treatments
-
Business
FDA takes action to remove biosimilars roadblock
The US Food and Drug Administration proposes system to name biosimilar drugs
-
OpinionA risky business
Graduate research is likely the most risky time of a chemist’s career, says Derek Lowe
-
Opinion
Drugs in a class of their own
New drug types need careful regulation to reward innovation while protecting patients
-
BusinessFemale sexual desire drug approved
Concerns raised over efficacy, side effects and use of advocacy campaigning to influence regulatory decisions
-
BusinessIndian pharma under increased regulatory scrutiny
Import bans and tightened rules pose a significant challenge for companies
-
BusinessPorous pills could be largest industrial 3D printing use
US grants first-of-a-kind approval for Aprecia’s epilepsy tablets exploiting porous structure
-
BusinessGreek crisis puts pressure on pharmaceuticals
Public spending cuts and capital restrictions on banks have exacerbated drug supply problems in Greece
-
BusinessNo one should be denied medication
Exclusive interview with Yusuf Hamied, chairman of Indian generic drugmaker Cipla
-
Business
Shire makes hostile bid for Baxalta
Recently spun-out from Baxter, Baxalta is resisting the deal, saying it wants time to prove its true value
-
Business
Grabbing slices of the immuno-oncology pie
Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’
-
Business
AstraZeneca sells off drugs to streamline portfolio
Crohn’s disease and rare thyroid cancer drugs lie outside firm’s renewed strategic focus
-
OpinionA precision instrument?
Chemists and biologists have different expectations when it comes to data, says Derek Lowe
-
Business
Celgene to buy immune-inflammatory specialist Receptos
$7.2bn deal further strengthens Celgene’s position in immunology
-
Business
Hikma boosts generics with Roxane buyout
Acquiring the Boehringer Ingelheim subsidiary expands Hikma’s presence in US generics market
-
Business
Allergan steps away from generics with sale to Teva
$40.5 billion deal gives Allergan cash to clear debt and fund further acquisitions, and catapults Teva into global pharma top 10
-
Business
Biogen to develop gene therapies with AGTC
$1bn deal gives Biogen rights to one clinical candidate and several earlier-stage programmes for rare eye diseases
-
BusinessChemical firms seek better grasp of biomanufacturing
The search is on for better alternatives to the ‘broken’ way companies harness compound-making organisms